The Role of the HPA Axis in Psychiatric Disorders and CRF Antagonists as Potential Treatments

  title={The Role of the HPA Axis in Psychiatric Disorders and CRF Antagonists as Potential Treatments},
  author={Paul A. Keller and Adam McCluskey and Jody Morgan and Sean M. J. O'Connor},
  journal={Archiv der Pharmazie},
An overview of the links between the Hypothalamic‐Pituitary‐Adrenal (HPA) axis and psychiatric disorders is presented. The current treatments are outlined, indicating that they are insufficient to meet the needs of those that suffer from these affective disorders. Therefore, there is an urgent need for the generation of new therapeutics, in particular, against new targets. The association of the corticotrophin releasing factor (CRF) and the HPA axis indicates that CRF antagonists should be… 

Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders

This review describes involvement of brain RAS in pathophysiology of neuropsychiatric disorders and an intriguing possibilities of improvement in pharmacological treatment outcome, where using angiotensin-converting-enzyme inhibitors (ACEI) and Angiotens in Receptor Blockers (ARB), goes beyond blood pressure control.

The Hypothalamic‐Pituitary‐Adrenal Axis in Borderline Personality Disorder: A Review

Findings are mixed but suggest that important variables relevant to between‐group differences include comorbid depression,Comorbid posttraumatic stress disorder, dissociative symptoms, and history of childhood abuse.

Impact of Glucocorticoid Receptor Polymorphisms on Glucocorticoid Action

  • M. SavasElisabeth F.C. van Rossum
  • Biology, Medicine
    Encyclopedia of Endocrine Diseases
  • 2019

Prenatal Stress Induces Schizophrenia-Like Alterations of Serotonin 2A and Metabotropic Glutamate 2 Receptors in the Adult Offspring: Role of Maternal Immune System

Pathophysiological hypotheses that propose an early neurodevelopmental origin for schizophrenia and other psychiatric disorders are strengthened, including that of prenatal stress on maternal care.

Role of corticosteroids in the antidepressant response

This work is distributed under the terms of the License

Stress and Obesity: Are There More Susceptible Individuals?

Stress may play a major role in the development and maintenance of obesity in individuals who have an increased glucocorticoid exposure or sensitivity and these insights may lead to more effective and individualized obesity treatment strategies.



The role of corticotropin-releasing factor in depression and anxiety disorders.

The hypothesis that CRF receptor antagonists may represent a novel class of antidepressants and/or anxiolytics, probably through its effects on central noradrenergic systems, is supported.

The role of Corticotropin Releasing Factor in Depressive Illness: a Critical Review

  • A. Mitchell
  • Psychology, Biology
    Neuroscience & Biobehavioral Reviews
  • 1998

Hypercortisolemia and depression.

The authors review the history of techniques used to assess the functions of the HPA axis, evidence for hypercortisolemia as a state rather than trait component of depression, and treatment implications.

The role of corticotropin-releasing factor in drug addiction.

The goal of this article is to summarize available data examining the physiological significance of brain corticotropin-releasing factor (CRF) systems in mediating the behavioral and physiological

Physiological and Neurochemical Aspects of Corticotropin-Releasing Factor Actions in the Brain: The Role of the Locus Coeruleus

The interaction of noradrenergic and CRF-neurons clearly implies that CRF appears to directly activate LC neurons in a stressful situation, thus ultimately coordinating the bodily response to a stressful stimulus.

Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.

Findings are concordant with the hypothesis that CRF hypersecretion is, at least in part, responsible for the hyperactivity of the hypothalamo-pituitary-adrenal axis characteristic of major depression.

The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress

Data confirm that R121919 acts as a CRF1 receptor antagonist in vivo, attenuates HPA axis responsivity, and possesses anxiolytic properties.